One patient carrying ASXL1, SETBP1 and RUNX1 mutations evolved to AML within seven years of the AA diagnosis; this patient was diagnosed with NSAA at the age of 47 and received oral cyclosporine therapy for two years, but the disease relapsed after discontinuation of the drug. This evidence concerns the gene SETBP1 and acute myeloid leukemia.